Cell Therapy Technologies Market

The report "Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Vessels, Single-Use Equipment), Process (Cell Processing, Preservation, Distribution, QC), Cell type (T-Cells, Stem cells), Application (Cancer, CVD), End user - Global Forecast to 2029", is projected to expand to a value of USD 6.80 billion in 2029 from USD 4.03 billion in 2024, with a significant CAGR of 11.0%. The cell therapy technologies market is driven by several key factors, including the rising prevalence of chronic diseases, advancements in regenerative medicine, and growing investment in biotechnology and healthcare infrastructure. Increasing demand for personalized medicine and the development of cutting-edge gene-editing tools, such as CRISPR, are significantly boosting market growth.

Browse 516 market data Tables and 55 Figures spread through 463 Pages and in-depth TOC on "Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Vessels, Single-Use Equipment), Process (Cell Processing, Preservation, Distribution, QC), Cell type (T-Cells, Stem cells), Application (Cancer, CVD), End user - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cell-therapy-technologies-market-213334978.html

The media, sera, and reagents segment accounted for the dominant share in 2023.

By product, the market is divided into media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products. In 2023, the Media, sera, and reagents hold a major market share driven by their critical role in enabling efficient cell culture, expansion, and preservation. The rising adoption of serum-free and chemically defined formulations has significantly enhanced process efficiency and reproducibility, aligning with industry demands for high-quality, scalable solutions.

Biopharmaceutical & biotechnology companies is likely to grow at significant CAGR during the forecast period for 2024-2029.

In terms of end user, the market has been classified into biopharmaceutical & biotechnology companies, CROS & CMOs, research institutes and cell banks. Biopharmaceutical & biotechnology is the largest market share contributor in 2023 owing to the extensive adoption of these advanced instruments such as cell expansion systems and single-use technologies for cell-based research and cancer research application. Additionally, a favorable regulatory environment, expedited approval pathways, increasing prevalence of chronic conditions and increasing global healthcare expenditure are supporting market expansion.

North America: The region dominated cell therapy technologies market.

Based on region the cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The Asia-Pacific (APAC) region is emerging as a significant growth hub in the cell therapy technologies market, driven by a combination of factors including increasing investments in healthcare infrastructure, expanding biotechnology sectors, and supportive government initiatives. The region benefits from a growing prevalence of chronic diseases and a rising focus on regenerative medicine, fueling demand for advanced cell therapy solutions. Countries like China, Japan, and South Korea are leading the charge with robust R&D activities and a surge in clinical trials.

Prominant players operating in the cell therapy technologies market include Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc.  (US), Avantor, Inc. (US),  Bio-Techne (US), Avantor, Inc. (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US) and among others.

Don’t miss out on business opportunities in Cell Therapy Technologies Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]